GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tarlatamab   Click here for help

GtoPdb Ligand ID: 12969

Synonyms: AMG 757 | AMG-757 | AMG757 | Imdelltra® | tarlatamab-dlle
Approved drug
tarlatamab is an approved drug (FDA (2024))
Compound class: Antibody
Comment: Tarlatamab (AMG 757) is a bispecific T cell engager (BiTE®) type anti-Delta-like ligand 3 (DLL3) monoclonal antibody [5-6]. It co-engages DLL3 on cancer cells and CD3E on T cells to promote T cell-mediated tumour lysis. The rationale for investigating DLL3 as a cancer drug target is reviewed in [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Tarlatamab (AMG 757) was progressed to clinical evaluation for the treatment of advanced solid tumours [1,7]. The FDA granted accelerated approval for the treatment of extensive stage small cell lung cancer (progressing during/following platinum-based chemotherapy) in May 2024 [4]. This accelerated approval was converted to regular approval in November 2025.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05740566 Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer Phase 3 Interventional Amgen
NCT03319940 Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) Phase 1 Interventional Amgen 6
NCT05060016 A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) Phase 2 Interventional Amgen 2